Amgen to Present at ASCO


Amgen will present data from several studies of both pipeline and marketed products at the 2013 American Society of Clinical Oncology Annual Meeting from May 31 to June 4 in Chicago. Abstracts will include study results on talimogene laherparepvec, an investigational oncolytic immunotherapy for the treatment of melanoma; blinatumomab in pediatric patients with acute lymphoblastic leukemia; and Vectibix (panitumumab) in metastatic colorectal cancer.

Facebook Comments


We’re glad to see you’re enjoying PracticalDermatology…
but how about a more personalized experience?

Register for free